We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




DNA-Based Droplet System Rapidly Detects Bacterial Infection in the Bloodstream

By LabMedica International staff writers
Posted on 23 Nov 2014
A new test for bacterial infection in the bloodstream is based on an innovative DNA labeling and particle counting system.

Investigators at the University of California, Irvine (USA) recently described a new technology termed "Integrated Comprehensive Droplet Digital Detection" (IC 3D) that can selectively detect bacteria directly from milliliters of diluted blood. More...
IC 3D is a one-step, culture- and amplification-free process that provides results with single-cell level sensitivity in from ninety minutes to four hours.

The IC 3D instrument converts blood samples into billions of minute droplets. Fluorescent DNA sensor solution infused into the droplets detects those with bacterial markers, marking them with an intense fluorescent signal. Separating the samples using real-time, DNAzyme-based sensors, droplet microencapsulation, and a high-throughput 3D particle counter system minimizes the interference of other components in blood, making it possible to directly detect target bacteria without the purification typically required in conventional assays.

Using Escherichia coli as a target, the investigators demonstrated that the IC 3D system could provide absolute quantification of both stock and clinical isolates of E. coli in spiked blood within a broad range of extremely low concentration from one to 10,000 bacteria per milliliter with exceptional robustness and limit of detection in the single digit range.

“We are extremely excited about this technology because it addresses a long-standing unmet medical need in the field,” said senior author Dr. Weian Zhao, assistant professor of pharmaceutical sciences at the University of California, Irvine. “As a platform technology, it may have many applications in detecting extremely low-abundance biomarkers in other areas, such as cancers, HIV and, most notably, Ebola.”

The study was published in the November 13, 2014, online edition of the journal Nature Communications.

Related Links:

University of California, Irvine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.